Drug Trial Radar · NCT06237335
A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF
Last checked: Nov 19, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
128
Actual
Start
Feb 1, 2024
Primary completion
Nov 2026
Study completion Nov 2026
Sponsor
- Lead sponsor
- ReCode TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Feb 1, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is the first-in-human study with RCT2100 and is designed to provide safety and tolerability data for future clinical studies.
Conditions
- Cystic Fibrosis
Interventions
RCT2100Drug
RCT2100 supplied as varying dose strengths administered via oral inhalation using nebulizer
PlaceboOther
Placebo of similar volumes to experimental dose strengths administered via oral inhalation using nebulizer
RCT2100Drug
RCT2100 supplied as varying dose strengths administered via oral inhalation using nebulizer for 4 weeks
RCT2100Drug
RCT2100 supplied at a single dose strength administered via oral inhalation using nebulizer for 12 weeks
IvacaftorDrug
ivacaftor administered orally for 6 weeks
RCT2100Drug
RCT2100 supplied at varying dose strengths. Co- administered via oral inhalation using nebulizer for 4 weeks with ivacaftor after initial 2 weeks of ivacaftor dosing run in period
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: The number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs).Time frame: From Baseline Through Day 29
- Part 2: The number of participants with CF with AEs and SAEs.Time frame: From Day 1 through Safety Follow-up, Week 24
- Part 3: The number of participants with CF with AEs and SAEs.Time frame: From Day 1 through Safety Follow-up, Week 24
Locations
23 sites in 5 countries. Site status is shown where the registry gives one.
The University of Alabama at Birmingham
Birmingham, Alabama
University of Arizona
Tucson, Arizona
Stanford University
Palo Alto, California
UCSD
San Diego, California
National Jewish Health
Denver, Colorado
Emory University
Atlanta, Georgia
Boston Children's Hospital
Boston, Massachusetts
New York Medical College
Valhalla, New York
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Oregon Health & Science University
Portland, Oregon
University of Pittsburgh
Pittsburgh, Pennsylvania
UT Southwestern Medical Center
Dallas, Texas
University of Washington
Seattle, Washington
Centre Hospitalier Régional Universitaire de Montpellier - Hôpital Arnaud de Villeneuve
Montpellier, France
Hôpital Necker Enfants Malades
Paris, France
UMC Utrecht
Utrecht, Netherlands
New Zealand Clinical Research (Part 1 Only)
Auckland, New Zealand
University Hospitals Birmingham
Birmingham, United Kingdom
Royal Papworth Hospital
Cambridge, United Kingdom
Leeds Teaching Hospitals
Leeds, United Kingdom
King's College Hospital
London, United Kingdom
Nottingham University Hospitals
Nottingham, United Kingdom
University Hospital Southampton
Southampton, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.